(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of -35.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 218.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Biolinerx's revenue in 2025 is $17,251,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2025 to be $3,981,075,060, with the lowest BLRX revenue forecast at $3,601,925,055, and the highest BLRX revenue forecast at $4,360,225,066. On average, 1 Wall Street analysts forecast BLRX's revenue for 2026 to be $16,421,934,624, with the lowest BLRX revenue forecast at $16,421,934,624, and the highest BLRX revenue forecast at $16,421,934,624.
In 2027, BLRX is forecast to generate $30,213,516,084 in revenue, with the lowest revenue forecast at $30,213,516,084 and the highest revenue forecast at $30,213,516,084.